Delving into the Latest Updates on Influenza virus vaccine (Il-Yang Pharmaceutical) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine

Synonyms

TERATECT Vaccine, Teratect vaccine (split influenza vaccine)

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza A virus infectionInfluenza B virus infection

Inactive Indication-

Originator Organization

IlYang Pharmaceutical Co., Ltd.

Active Organization

IlYang Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

South Korea (04 Jan 2024),

Influenza A virus infectionInfluenza B virus infection

Regulation-

Login to view timeline

AbstractMucosal delivery systems have gained much attention as effective way for antigen delivery that induces both systemic and mucosal immunity. However, mucosal vaccination faces the challenges of mucus barrier and effective antigen uptake and presentation. In particular, split, subunit and recombinant protein vaccines that do not have an intact pathogen structure lack the efficiency to stimulate mucosal immunity. In this study, poly (lactic acid-co-glycolic acid-polyethylene glycol) (PLGA-PEG) block copolymers were modified by mannose to form a PLGA-PEG-Man conjugate (mannose modified PLGA-PEG), which were characterized. The novel nanoparticles (NPs) prepared with this material had a particle size of about 150 nm and a zeta potential of −15 mV, and possessed ideal mucus permeability, immune cell targeting, stability and low toxicity. Finally, PLGA-PEG-Man nanoparticles (PLGA-PEG-Man NPs) were successfully applied for intranasal delivery of split influenza vaccine in rat for the first time, which triggered strong systemic and mucosal immune responses. These studies suggest that PLGA-PEG-Man NPs could function as competitive potential nano-adjuvants to address the challenge of inefficient mucosal delivery of non-allopathogenic antigens.

11 Dec 2023·ACS Biomaterials Science & Engineering

Coated Porous Microneedles for Effective Intradermal Immunization with Split Influenza Vaccine

Article

Author: Li, Zhipeng ; Ma, Shichao ; Su, Rui ; Xiu, Xueliang ; Li, Xuemei ; Ma, Fengsen ; Zhang, Li

In order to alleviate the pain associated with subcutaneous injections, microneedles (MNs) are gaining increasing attention as a novel transdermal drug delivery modality. Among them, porous microneedles (pMNs) are particularly suitable for the delivery of drugs and vaccines whose activity is sensitive to the microneedle preparation process. They can carry drugs actively to achieve an effective load and deliver drugs into the skin. In this study, the biocompatible cellulose acetate (CA) microporous MNs with a large pore size of 1.13 μm ± 0.45 and a high porosity of 74.8% ± 2.8% were prepared by using a safe nonsolvent-induced phase separation (NIPS) method. The MN patches prepared after adsorption of appropriate concentrations of split influenza vaccine fully met the dose loading requirements. A biocompatible carboxymethyl cellulose (CMC) solution was used in the pMN coating to strengthen their mechanical properties, with an average maximum stress of 32.89 N, and to act as a medium for the dispersion of an adjuvant in the coating layer. The influenza vaccine adsorbed in the micropore and the adjuvant dispersed in the coating were released intradermally to exert synergistic effects with different release patterns and rates. The coated pMNs induced an efficient immune response in Wistar rats with a hemagglutination inhibition (HI) titer of ≥1024, which was comparable to that of intramuscular injection. The research is organized around the goal of engineering exploration of innovative technologies, suggesting that pMNs have a tantalizing prospect for future applications. It opens up the possibility of eventually obtaining a simple, easy-to-use, and efficient application technology for the prevention of global epidemics like influenza.

01 Apr 2023·Endocrinology, Diabetes & Metabolism Case Reports

Fulminant type 1 diabetes developed after influenza split vaccination

Article

Author: Kometani, Mitsuhiro ; Sawada, Kei ; Aono, Daisuke ; Yoneda, Takashi ; Karashima, Shigehiro ; Takeda, Yoshiyu ; Sawamura, Toshitaka ; Ohmori, Ai

SummaryFulminant type 1 diabetes (FT1D) is a subtype of diabetes characterized by rapid progression of β-cell destruction, hyperglycemia, and diabetic ketoacidosis (DKA). The pathogenesis of this disease remains unclear. However, viral infections, HLA genes, and immune checkpoint inhibitor use were reportedly involved in this disease. A 51-year-old Japanese man with no chronic medical condition was admitted to our hospital with complaints of nausea and vomiting. Cough, sore throat, nasal discharge, and diarrhea were not noted. He had a medical history of at least two influenza infections. His vaccination history was notable for receiving an inactive split influenza vaccine 12 days prior to developing these symptoms. He was diagnosed with DKA associated with FT1D. His HLA class II genotypes were nonsusceptible to FT1D, and he had a negative history of immune checkpoint inhibitor use. The destruction of the pancreas by cytotoxic T cells is reported to be involved in FT1D. Inactive split influenza vaccines do not directly activate cytotoxic T cells. However, these could activate the redifferentiation of memory CD8-positive T cells into cytotoxic T cells and induce FT1D, as this patient had a history of influenza infections.Learning points

Influenza split vaccination could cause fulminant type 1 diabetes (FT1D).

The mechanism of influenza split vaccine-induced FT1D might be through the redifferentiation of CD8-positive memory T cells into cytotoxic T cells.

100 Deals associated with Influenza virus vaccine (Il-Yang Pharmaceutical)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB01	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Influenza A virus infection	South Korea	IlYang Pharmaceutical Co., Ltd.	04 Jan 2024
Influenza B virus infection	South Korea	IlYang Pharmaceutical Co., Ltd.	04 Jan 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Discovery	United States	IlYang Pharmaceutical Co., Ltd.	01 Nov 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02263131 (CTgov)	Phase 3	Influenza, Human	416	IL-YANG FLU Vaccine Prefilled Syringe INJ. (IL-YANG PFS)	xuaavgwgyd(effujjptrl) = qncpbqozac ifgulyallb (kfsnqtjonh, siyszgvgow - kbvnihemqk) View more	-	06 Apr 2015
				VAXIGRIP Prefilled Syringe INJ. (TIV PFS)	xuaavgwgyd(effujjptrl) = duyarjqoah ifgulyallb (kfsnqtjonh, geyeevdano - zggblytbpf) View more